InvestorsHub Logo
Followers 237
Posts 10817
Boards Moderated 0
Alias Born 07/17/2006

Re: Greymatter1 post# 205529

Saturday, 08/03/2019 4:16:01 PM

Saturday, August 03, 2019 4:16:01 PM

Post# of 426485
Greymatter...

Who are you to say a CEO should not worry about the fluctuations in the stock price...I say maintaining the PPS is one of the main duties of a CEO if not his most important duty...

We are currently seeing the results when a CEO does not pay enough attention..The market cap has gone down 15% adjusted for the stock dilution and the the overall movement of the stock market...That is we have picked up about $440 mil in cash and we have lost just under $ .9 bil in market cap...Not much of a deal...

This could have been and should have been avoided simply by waiting two months when we would (according to JT at the recent Q-report..be getting the sNDA).

With the Vascepa sNDA in hand Amarin is a different animal..one which will be accorded a lot more respect with the most. Vascepa would be the most effective CVD event reducing drug since the advent of Statins...The PPS would be higher meaning less dilution and perhaps the stock would not be discounted almost 20% which is was in this offering,,

Apparently JT does not think the stock shares are worth much...And neither do the people he sold these shares to as they are selling them as fast as they can get their hands on them, And that is dropping the PPS like a rock in a well..If the CEO doesn't think much of shares..why should anyone else...

":>) JL
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News